Ruga, P. (HIV) (10, 15, 17). The follow-up of illness in newborns may elucidate some aspects of disease development; the HCV variant recognized at birth may be regarded as the starting viral sequence for a particular sponsor, allowing a more reliable analysis of sequence variability over time. This study evaluates the pace of HCV transmission from HCV RNA-positive anti-human immunodeficiency disease (HIV) antibody-negative mothers to their offspring and the medical evolution of acquired illness. We carried out a longitudinal study of 33 anti-HCV-positive babies for 24 months, and two infected children belonging to this cohort were followed up until 5 or 6 years of age by evaluating several medical and virological guidelines and sequencing hypervariable areas (HVR) of the putative envelope-encoding E2 region of the HCV genome (5, 7, 8). Longitudinal study. In our study 2,263 anti-HIV antibody-negative pregnant women were screened for anti-HCV antibodies between June 1992 and June 1995; anti-HCV antibody positivity was found in 56 instances (2.4%), and 33 ladies were enrolled in a prospective longitudinal study of HCV transmission. Their age groups ranged between 19 and 42 years (imply age, 28 years); 20 ladies (60%) experienced an acknowledged SR 3677 dihydrochloride history of intravenous drug use, 1 (3%) was a health care worker with professional exposure (3%), 4 (12%) experienced an acknowledged history of anti-HCV antibody-positive sexual partners, and 8 (24%) experienced no risk element. No woman was in interferon therapy. Only 2 pregnant women were diagnosed as chronic hepatitis sufferers based on histological findings by liver biopsy, and 26 were asymptomatic. Four ladies breast fed up to 10 to 12 months, and two breast fed up to 30 days. All but 3 of 33 babies were delivered vaginally. Serum samples were stored at ?80C within 3 h of collection in a day hospital. Screening for anti-HCV antibodies was carried out by a commercially available third-generation enzyme immunoassay (EIA; Abbott); positive results acquired by EIA were confirmed by a third-generation recombinant immunoblot assay (RIBA) (Ortho Diagnostic), and serum alanine aminotransferase (ALT) levels were determined. The test for anti-E2 antibodies was carried out by HCV E2 immunoglobulin G (IgG) kit EIA (Nuclear Laser Medicine) in instances of transmission of the illness. Total RNA was extracted from 100 l of serum by using the guanidine thiocyanate method and was recognized by reverse transcriptase PCR and nested PCR by using two units of oligonucleotide primers deduced from your highly conserved 5 untranslated region of the HCV genome (1-3). Quantification of HCV RNA in serum was performed from the Amplicor HCV Monitor (Roche Diagnostic Systems, Branchburg, N.J.), and HCV genotypes were identified through a collection probe assay (INNO-LiPA; Innogenetics, Nucear Laser Medicine). A 447-bp sequence of the E2 region encompassing HVR1 and HVR2 of the HCV genome (from nucleotide [nt] 1324 to nt 1771) was amplified by heminested reverse transcriptase PCR. E2 cDNA was acquired with an E2A antisense primer (5-TTCATCCAGGTGCASCCGSAA-3; nt 1986 to 1966) and amplified with E2A and E2S (5-CCYGGTTGCTCYTTYTCTATCTT-3; nt 848 to 870) primers. A second amplification was performed with E2A and E2NA (5-GGTGGGTAGTGCCAGCAATA-3; nt 1813 to Esm1 1794) primers. Crude PCR products were used as themes for a cycle SR 3677 dihydrochloride sequencing reaction with the Thermo Sequenase cycle kit (Amersham, Little Chalfont, United Kingdom) and an infrared IRD 800-labeled E2-specific sequencing MB primer (5-GCATGGCTTGGGATATGATG; nt 1291 to 1310). Termination products were electrophoresed and analyzed inside a model 4000L Licor DNA sequencer (Molecular Biotechnology) (18). Computer analysis of the sequence data was performed with Chromas, version 1.51 (Technelysium Pty. Ltd.). Nucleotide and deduced amino SR 3677 dihydrochloride acid sequences were aligned with the CLUSTALW system, and synonymous and nonsynonymous nucleotide mutations were evaluated. Mother-child distances were computed by DNADIST of the Philip, version 3.57, package according to the Kimura model. The test for equality of means of.